Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Nov 9;33(45):6106-11.
doi: 10.1016/j.vaccine.2015.07.111. Epub 2015 Aug 28.

Recent advances in the study of live attenuated cell-cultured smallpox vaccine LC16m8

Akiko Eto  1 , Tomoya Saito  1 , Hiroyuki Yokote  2 , Ichiro Kurane  3 , Yasuhiro Kanatani  4
Affiliations
Review

Recent advances in the study of live attenuated cell-cultured smallpox vaccine LC16m8

Akiko Eto et al. Vaccine. .

Abstract

LC16m8 is a live, attenuated, cell-cultured smallpox vaccine that was developed and licensed in Japan in the 1970s, but was not used in the campaign to eradicate smallpox. In the early 2000s, the potential threat of bioterrorism led to reconsideration of the need for a smallpox vaccine. Subsequently, LC16m8 production was restarted in Japan in 2002, requiring re-evaluation of its safety and efficacy. Approximately 50,000 children in the 1970s and about 3500 healthy adults in the 2000s were vaccinated with LC16m8 in Japan, and 153 adults have been vaccinated with LC16m8 or Dryvax in phase I/II clinical trials in the USA. These studies confirmed the safety and efficacy of LC16m8, while several studies in animal models have shown that LC16m8 protects the host against viral challenge. The World Health Organization Strategic Advisory Group of Experts on Immunization recommended LC16m8, together with ACAM2000, as a stockpile vaccine in 2013. In addition, LC16m8 is expected to be a viable alternative to first-generation smallpox vaccines to prevent human monkeypox.

Keywords: Anti-terrorism; LC16m8; Monkeypox; Smallpox vaccine.

PubMed Disclaimer

References

    1. Hashizume S., Yoshizawa H., Morita M., Suzuki K. In: Vaccinia viruses as vectors for vaccine antigens. Quinnan G.V., editor. Elsevier Science Publishing Co. Inc.; New York: 1985. Properties of attenuated mutant of vaccinia virus, LC16m8, derived from Lister strain; pp. 87–99.
    1. Yamaguchi M., Kimura M., Hirayama M. Report of the National Smallpox Vaccination Research Committee: study of side effects, complications and their treatments. Rinsho to Uirusu. 1975;3:269–278. (in Japanese)
    1. Kidokoro M., Tashiro M., Shida H. Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8. Proc Natl Acad Sci U S A. 2005;102:4152–4157. - PMC - PubMed
    1. Arita I. Smallpox vaccine and its stockpile in 2005. Lancet Infect Dis. 2005;5:647–652. - PubMed
    1. Saito T. Research on preparedness for bioterrorism-associated events in Japan: smallpox vaccine preparedness. J Disaster Res. 2009;4:329–336.

Publication types